Skip to NavigationSkip to content

Top Ten most popular articles on this week

Published on 05/10/18 at 12:12pm

As September came to a close and October began the UK was hit hard in the headlines after American firm Recardio halted clinical trials in Scotland and England while the government were accused of using Brexit to avoid EU led antibiotic resistance legislation.

However innovations in immunotherapy gave hope to those with HIV after an antibody was found to be able to supress the virus for months at a time while NHS England decided to fund Janssen’s HIV treatment Symtuza.

Meanwhile it was revealed that a man died after a leukaemia cell had been mixed in with cells being manufactured into CAR T therapies, while Novo Nordisk cut 650 jobs worldwide in a major R&D overhaul. Check out this week’s top 10 stories at!

10. NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza

Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its once-daily single tablet regimen of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), meaning affected individuals will be able to access the drug through regular clinician prescriptions across England.

9. Roche acquires immuno-oncology biotech Tusk in €655m deal

Swiss multinational Roche has acquired the privately held immuno-oncology company Tusk Therapeutics in a deal that could be worth up to €655 million.

8. UK government accused of using Brexit to avoid antimicrobial resistance ruling

The British government has been accused of using Brexit to avoid implementing new EU legislation preventing powerful antibiotics from be used in farming.

7. European countries unprepared for Alzheimer's innovations, study shows

European healthcare systems are not prepared for new developments in preventative therapies for Alzheimer’s disease, according to research conducted by the American non-profit think tank, the RAND Corporation.

6. Novo Nordisk cuts 650 roles around the world in R&D restructure

Novo Nordisk has announced a wave of jobs cuts as part of a global restructure of its $1 billion R&D business to drive diversification of its pipeline in chronic diseases, affecting hundreds of positions across its operations around the world.

5. Antibody therapy supresses HIV for months after treatment, study shows

Researchers from the New York City based Rockefeller University have developed a novel immunotherapy, which is capable of suppressing HIV for months at a time.

4. Lilly's Verzenio gets first-line EU approval for HER2- advanced breast cancer

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged.

3. Are biosimilars key to solving NHS access concerns?

In light of continued austerity gripping the NHS, it was uplifting to hear in July that the health service had generated millions in savings by switching to off-brand medications. Biosimilars formed a key part of this strategy, as Matt Fellows discovers.

2. 20 year old man died after leukaemia cell was accidently mixed into CAR T therapy

A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that were being manufactured into a CAR-T cell therapy, according to researchers at the University of Pennsylvania.

1. Clinical trial halted because of Brexit, UK Government downplays concerns

A clinical trial looking into the safety and efficacy of the drug dutogliptin has been halted due to uncertainties surrounding Brexit.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches